Q4 2024 Akebia Therapeutics Inc Earnings Call Transcript
Key Points
- Akebia Therapeutics Inc (AKBA) reported strong early demand for Vafseo, with expected net product revenue between $10 million and $11 million for Q1 2025, exceeding analyst estimates.
- The company has secured commercial supply contracts with dialysis providers covering nearly 100% of dialysis patients in the US, facilitating broad access to Vafseo.
- Over 500 physicians have prescribed Vafseo since its launch, with an average of approximately eight prescriptions each, indicating strong initial prescriber engagement.
- Positive early feedback from physicians and strong participation in peer-to-peer programs suggest high interest and potential for Vafseo to become a standard of care.
- Akebia Therapeutics Inc (AKBA) has a robust distribution network that has helped manage initial prescription backlogs, ensuring better access to Vafseo for patients.
- Total revenues for Q4 2024 decreased to $46.5 million from $56.2 million in Q4 2023, reflecting a decline in Auryxia net product revenues.
- The company reported a net loss of $22.8 million in Q4 2024 compared to net income of $0.6 million in Q4 2023, impacted by lower revenues and non-cash interest expenses.
- There is a backlog in prescription fulfillment for Vafseo and other TDAPA products, with some delays exceeding three weeks, affecting patient access.
- The transition of prescriptions to specialty pharmacies has caused operational challenges, impacting the timely delivery of Vafseo to patients.
- The company does not plan to provide quarterly revenue guidance going forward, which may limit visibility for investors on future financial performance.
Good day, and welcome to Akebia's fourth-quarter 2024 financial results call. (Operator Instructions) As a reminder, this call may be recorded.
I would now like to turn the call over to Mercedes Carrasco, Senior Director, Investor Relations. Please go ahead.
Thank you, and welcome to Akebia's fourth-quarter and full-year 2024 financial results and business update conference call. Please note that a press release was issued earlier today, Thursday, March 13, detailing our fourth quarter and full year 2024 financial results and that release is available on the investors section of our website. For your convenience, a replay of today's call will also be available on our website after we conclude.
Joining me for today's call, we have John Butler, Chief Executive Officer; Nick Grund, Chief Commercial Officer; and Erik Ostrowski, Chief Financial and Chief Business Officer.
I'd like to remind everyone that this call includes forward-looking statements. Each
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
